Bambusa Therapeutics
Boston, Massachusetts, United States · Biotechnology, Health Care · 12 employees
Bambusa Therapeutics believes the I&I field is long overdue for innovative approaches and transformative therapeutics. Since our inception, we have built a diverse portfolio of molecules and are uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions.
Funding history
- Series series a — Undisclosed — Nov 2025
- Funding Round — $53.3M — Feb 2025
- Series series a — $90.0M — Feb 2025
Recent signals
- Mar 19, 2026: Bambusa Therapeutics Appoints Todd James as Chief Financial Officer
- Nov 17, 2025: Raised funding in Series series a
- Feb 26, 2025: Raised $53.3M
- Feb 14, 2025: Raised $90.0M in Series series a
See plans & pricing → Track Bambusa Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.